MedTrace Logo

Epigenetics, Vitamin C and Abnormal Hematopoiesis - Pilot Study

NCT02877277 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2018-09-24

No results posted yet for this study

Summary

This study evaluates whether vitamin C improves responses to epigenetic therapy with DNMTis. Half of the patients will receive vitamin C and DNMTi while the other half will receive placebo and DNMTi.

Conditions

Interventions

DIETARY_SUPPLEMENT

Vitamin C

Oral intake of vitamin C tablet (500 mg) daily for 56 days

DIETARY_SUPPLEMENT

Placebo

Oral intake of placebo tablet daily for 56 days

Sponsors & Collaborators

  • Van Andel Research Institute

    collaborator OTHER

  • Rigshospitalet, Denmark

    lead OTHER

Principal Investigators

  • Kirsten Grønbæk, Professor · Rigshospitalet, Denmark

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-08-08
Primary Completion
2017-05-29
Completion
2017-05-29

Countries

  • Denmark

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02877277 on ClinicalTrials.gov